SEATTLE--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ:GENZ), a Cambridge, Massachusetts-based biotechnology company is the target of an investigation by Seattle-based shareholder-rights law firm Hagens Berman Sobol Shapiro (HBSS), following reports that Genzyme may have delayed news concerning manufacturing problems.
